Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Information about Attana’s presentation at Stora Aktiedagen streamed live on December 2[nd] 09:00-09:30

Attana will participate at Stora Aktiedagen where CEO Teodor Aastrup will give a 20-minute company presentation followed by a 10-minute Q&A session. Both will be live streamed on December 2[nd] from 09:00 to 09:30.The presentation will focus on where Attana stands today, where the company is heading and the plan for getting there. This includes a presentation of the exciting projects planned for 2021, enabled by the upcoming rights issue. Tentative schedule: 1. Attana in short– Attana’s product and service offering 2. Recent milestones– Important milestones during 2020 3.

Realfiction intends to carry out a directed issue of units

Not for release, publication or distribution in whole or in part, directly or indirectly, in the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Singapore, South Africa, South Korea or any other jurisdiction where such release, publication or distribution would be unlawful or would require registration or anu other measures. Please refer to important information at the end of the press release. Realfiction Holding AB (”Realfiction” or the ”Company”) today announces its intention to carry out a directed issue of units of approximately SEK 35.8 million, each unit consisting

Positive discussions at SpectraCure's Investigator Meeting

SpectraCure has held an Investigator Meeting where the topic of discussion was statistics and results from the treatments conducted in the Company's clinical study. The discussions at the meeting will also form the basis of the forthcoming application for Accelerated Approval. Physicians and representatives of the hospitals included in the study participated in the meeting: University College London Hospital, Princess Margaret Cancer Centre in Toronto, University of Pennsylvania Hospital in Philadelphia and Memorial Sloan Kettering Cancer Center in New York."On the basis of the positive

Irisity wins SL's extensive procurement of video analysis for the metro

Irisity AB (publ) has been chosen by AB Storstockholms Lokaltrafik to deliver the deep learning algorithm IRIS Rail to the Stockholm metro.IRIS Rail detects track time in the subway in real time as well as so-called "dwell time" and "loitering" for abandoned objects or a person lying on a bench, for example. IRIS Rail also detects deviant behavior in the station environment. The order value is estimated at approximately SEK 4 million. In accordance with LOU, a contract lock for 10 days applies.   For further information: Jonas Andrén, Enterprise Sales Phone: +46 (0)735 20 73

The Danish Business Authority (“Erhvervsstyrelsen”) requires Lundbeck to conduct a new impairment test for 2017 leading to a reversal of an impairment loss on Rexulti (brexpiprazole)

· Lundbeck’s FY 2020 financial guidance for revenue, EBITDA and Core EBIT is maintained · The reversal of the impairment loss is expected to increase the annual amortizations and thereby reduce the company’s FY 2020 financial guidance for reported EBIT from previously DKK 2.0 – 2.2 billion to approximately DKK 1.7 – 1.9 billion · The adjustment does not generate any cash effect to Lundbeck · Lundbeck has not changed its expectations to Rexulti[® ]since 2015, although changes in timing and amounts of cash flows have occurred throughout the years · Lundbeck accepts the decision

#20-429 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Diaverum withdraws initial public offering

Following the announcement of its intention to float on 16 November 2020, Diaverum AB (publ.) (“Diaverum” or the “Company”), a leading global dialysis provider, today announces it will not proceed with the planned listing on Nasdaq Stockholm.Martin Dunn, member of the board of directors of Diaverum and partner at Bridgepoint, commented: “Despite strong interest from potential investors, including several high quality pension funds, who recognised Diaverum’s impressive underlying performance and ability to grow both revenues and earnings year on year, indications received did not fully

Calliditas Therapeutics’ nomination committee for the AGM 2021

Calliditas Therapeutics AB (publ.) publishes the nomination committee’s composition for the AGM in 2021.The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017, consists of: • Patrick Sobocki, appointed by Stiftelsen Industrifonden • Spike Loy, appointed by BVF • Karl Tobieson, appointed by Linc AB • Elmar Schnee (chairman of the board of directors) The nomination committee shall, before the annual general meeting 2021, prepare a proposal for the election of chairman and other members of

Bluestep Bank divests its personal loan portfolio to Svea Ekonomi

Bluestep Bank AB has entered into an agreement with Svea Ekonomi to divest its portfolio of unsecured personal loansIn the beginning of February 2020 Bluestep Bank decided to stop offering personal loans in order to entirely focus the strategic direction on mortgage products. The personal loan portfolio has since then been in run-off. Currently the personal loans represent 5% of Bluestep’s loan portfolio. The remaining 95% is mortgages. Discussions about potential divestment were initiated during the fall and interest for the portfolio has been strong.“It feels reassuring that the

European Commission approves Vestas and Mitsubishi Heavy Industries transaction to strengthen partnership in sustainable energy

Press Release from Vestas Wind Systems A/SAarhus, 27 November 2020 Recently Vestas Wind Systems A/S (Vestas) and Mitsubishi Heavy Industries, Ltd. (MHI) announced an agreement to expand their partnership in sustainable energy. The strengthened partnership entails that Vestas will acquire MHI’s shares in the MHI Vestas Offshore Wind (MVOW) joint venture, and MHI will acquire 2.5 percent in Vestas and be nominated to a seat in Vestas’ Board of Directors. The transaction between Vestas and MHI was subject to regulatory approvals by the competition authorities and with reference to

Agreement to acquire offshore business in joint venture approved by competition authorities

Vestas Wind Systems A/S, Aarhus, 27 November 2020Company announcement no. 42/2020   Agreement to acquire offshore business in joint venture approved by competition authorities Recently Vestas Wind Systems A/S (Vestas) and Mitsubishi Heavy Industries, Ltd. (MHI) announced an agreement to expand their partnership in sustainable energy. The strengthened partnership entails that Vestas will acquire MHI’s shares in the MHI Vestas Offshore Wind (MVOW) joint venture, and MHI will acquire 2.5 percent in Vestas and be nominated to a seat in Vestas’ Board of Directors, ref. Company

Moberg Pharma publishes audited interim report for the period July 2019 – September 2020

STOCKHOLM, November 27[th], 2020 – On November 10[th], 2020, Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) published its interim report for the period July 2019 – September 2020. The Company today publishes an audited interim report for the same period. The audit has not resulted in any adjustments to the financial numbers published on November 10[th], 2020.The audit of the interim report has been carried out due to the contemplated rights issue in the Company and the prospectus that is being prepared in connection thereto. The audited interim report is available in Swedish on

ODI Pharma AB: Publication of the interim report for Q1 2020

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July – September 2020. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.CEO Derek Simmross comments “Like everyone else, we had hoped to start our new fiscal year without the Covid-19 pandemic, but unfortunately it seems like it will continue to affect people, societies and economies across the globe. During this quarter, we have continued to invest a lot of time and effort on internal business

Media advisory: What a Biden Presidency means for global anti-corruption advocacy

Sen. Sheldon Whitehouse, Rep. Tom Malinowki and Manhattan DA Cyrus Vance take part in virtual panel at the 19[th] International Anti-Corruption Conference on 3 DecemberPresident-elect Joe Biden has promised to “re-engage in the world,” including on anti-corruption issues. He has criticized corrupt and authoritarian regimes, pledged to support multilateral agreements to fight corruption by updating U.S. laws and rules and joining forces with allies overseas. He has promised to lead efforts internationally to bring transparency to the global financial system, and he has committed to hosting a

First day of trading with warrants of series TO4

As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the current shareholders in the Company for the dilution that the previously conducted directed issue of shares and warrants entails. In this context, the Company simultaneously announces that the first day for trading with warrants of series TO4 on Nasdaq First North Growth Market has been set to

Episurf Medical enters into international advisory agreement

Episurf Medical (Nasdaq: EPIS B) today announces that the company has entered into an advisory agreement with Prof. Doctor João Espregueira-Mendes regarding establishment of the Episealer® knee technology in India and Portugal. The parties will work with a targeted strategy, targeting the orthopaedic communities in the aforementioned countries. Prof. Doctor João Espregueira-Mendes has extensive experience from the global orthopaedic markets and will assist Episurf Medical in key strategic activities. Prof. Doctor João Espregueira-Mendes is the Clinical Director of Clínica do Dragão -

Lehto Group Plc: Managers' Transactions

Lehto Group PlcManagers' Transactions November 27, 2020 at 3.07 p.m. (EET)Lehto Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Heikkilä, Jaakko Position: Other senior manager Issuer: Lehto Group Oyj LEI: 743700YEHY9I3ZDHNX66 Notification type: INITIAL NOTIFICATION Reference number: 743700YEHY9I3ZDHNX66_20201127130010_4 ____________________________________________ Transaction date: 2020-11-25 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: FINANCIAL INSTRUMENT

Lehto Group Plc: Managers' Transactions

Lehto Group PlcManagers' Transactions November 27, 2020 at 3.06 p.m. (EET)Lehto Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Räsänen, Mikko Position: Member of the Board/Deputy member Issuer: Lehto Group Oyj LEI: 743700YEHY9I3ZDHNX66 Notification type: INITIAL NOTIFICATION Reference number: 743700YEHY9I3ZDHNX66_20201127121446_3 ____________________________________________ Transaction date: 2020-11-26 Venue not applicable Instrument type: SHARE ISIN: FI4000081138

Lehto Group Plc: Managers' Transactions

Lehto Group PlcManagers' Transactions November 27, 2020 at 3.05 p.m. (EET)Lehto Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Törrönen, Kaarle Position: Other senior manager Issuer: Lehto Group Oyj LEI: 743700YEHY9I3ZDHNX66 Notification type: INITIAL NOTIFICATION Reference number: 743700YEHY9I3ZDHNX66_20201127122112_4 ____________________________________________ Transaction date: 2020-11-25 Venue not applicable Instrument type: SHARE ISIN: FI4000081138 Nature

Lehto Group Plc: Managers' Transactions

Lehto Group PlcManagers' Transactions November 27, 2020 at 3.04 p.m. (EET)Lehto Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Reiniluoto, Timo Position: Other senior manager Issuer: Lehto Group Oyj LEI: 743700YEHY9I3ZDHNX66 Notification type: INITIAL NOTIFICATION Reference number: 743700YEHY9I3ZDHNX66_20201127122032_6 ____________________________________________ Transaction date: 2020-11-25 Venue not applicable Instrument type: SHARE ISIN: FI4000081138 Nature

There are no items matching the current filter
There are no more items matching the current filter
Back to top